The efficacy, safety, and stability of tacrolimus 0.03% ointment in treatment of nonsegmental vitiligo | ||
| Journal of Current Medical Research and Practice | ||
| Volume 5, Issue 1, January 2020, Pages 41-45 PDF (350.23 K) | ||
| DOI: 10.4103/JCMRP.JCMRP_72_19 | ||
| Authors | ||
| Nagwa E. AbdElazim; Haidy A. Yassa; Ayman M. Mahran | ||
| Abstract | ||
| Background Topical immunoarm adulators have been successfully used as a monotherapy or in combination with other therapeutic modalities in vitiligo treatment. Topical tacrolimus has been reported to promote melanoblast differentiation and groth. Additionally, it promotes a favorable environement that enhances the proliferation of melanocytes/ melanoblasts through an interaction with keratinocytes, and thereby repopulating vitigiginous skin lesions. Aim To detect the effect of tacrolimus ointements in treatment of nonsegmental vitiligo. Method A total of 35 patients with vitiligo were enrolled in Tacrolimus this randomized placebo-controlled study. Two vitiliginous patches were chosen in each patient. The firstt lesion (A) was treated by tacrolimus 0.03% ointment, and the second lesion (B) was treated by panthenol cream as a placebo. Treatment course was 3 months, and follow-up was done for three extra months. Vitiliginous patches were assessed at baseline and monthly for 6 months. Results Moderate to excellent response was observed in 25.7% of lesions A compared with 0% of lesions B ( = 0.002). Disease duration has a negative effect on therapeutic response. No adverse effects were noted to tacrolimus ointment except for mild erythema in 6% of the patients. Coclusion Given its immunomodulatory properties and lack of cutaneous adverse effects, tacrolimus is a potential therapeutic alternative for vitiligo, with an improved benefit-risk ratio. | ||
| Keywords | ||
| immunomodulatory; Tacrolimus; vitiligenous | ||
|
Statistics Article View: 51 PDF Download: 23 |
||
